Exhibit 99.1

cdlxfy2017earningsrelimage.jpg

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As previously disclosed by Cardlytics, Inc. (the “Company”) on a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on January 26, 2026 (the “Prior Current Report”), on January 23, 2026, the Company, PAR Technology Corporation (“PAR”) and DB Sub, LLC, an indirectly wholly owned subsidiary of PAR (“Buyer”), entered into an asset purchase agreement (the “Purchase Agreement”), pursuant to which Buyer agreed to acquire all of the Company’s assets, properties and rights primarily related to, or primarily used in, the Company’s Bridg platform (the “Transaction”), subject to certain exceptions.

The Unaudited Pro Forma Condensed Consolidated Financial Statements presented below have been derived from the Company’s historical consolidated financial statements and give pro forma effect to the Transaction. The Unaudited Pro Forma Condensed Consolidated Balance Sheet as of December 31, 2025 reflects the Company’s financial position as if the Transaction had occurred on December 31, 2025. The Unaudited Pro Forma Condensed Consolidated Statements of Operations for each of the years ended December 31, 2025, 2024 and 2023 reflect the results of operations as if the Transaction had occurred on January 1, 2023 in that they reflect the reclassification of the Bridg business as discontinued operations for all periods presented.

The Unaudited Pro Forma Condensed Consolidated Financial Statements presented below have been derived from, and should be read in conjunction with, the Company’s audited consolidated financial statements and the notes thereto as of December 31, 2025, and for the three years ended December 31, 2025, and Management’s Discussion and Analysis included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Upon entering into the Agreement with the Buyer, the historical financial results of the Bridg business will be reflected in the Company’s consolidated financial statements as discontinued operations under U.S. generally accepted accounting principles for all periods presented.

The Unaudited Pro Forma Condensed Consolidated Financial Statements are presented based on information currently available, subject to the assumptions and adjustments described in the accompanying notes and is not intended to represent what the Company’s condensed consolidated balance sheet and statements of operations actually would have been had the Transaction occurred on the dates indicated above. Further, the Unaudited Pro Forma Condensed Consolidated Financial Statements are provided for illustrative and informational purposes only and are not necessarily indicative of the Company’s financial position and results of operations for any future period and does not reflect all actions that may be undertaken by the Company following the closing of the Transaction. In addition, the Unaudited Pro Forma Condensed Consolidated Financial Statements do not reflect the realization of any expected cost savings, synergies or dis-synergies as a result of the Transaction. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. Management believes these assumptions and adjustments are reasonable, given the information available at the time of filing. The Transaction constituted a significant disposition for purposes of Item 2.01 of Form 8-K and the Unaudited Pro Forma Condensed Consolidated Financial Statements presented below have been prepared in accordance with Article 11 of Regulation S-X, Pro Forma Financial Information.

The pro forma adjustments are based on currently available information and assumptions management believes are, under the circumstances and given the information available at this time, reasonable, and best reflect the Transaction on the Company’s financial condition and results of operations. The adjustments included within the “Discontinued Operations” column of the Unaudited Pro Forma Condensed Consolidated Financial Statements are the Company’s current preliminary estimates on a discontinued operations basis and could change as the Company finalizes discontinued operations accounting to be reported in the Company’s Quarterly Reports on Form 10-Q for the three months ending March 31, 2026, six months ending June 30, 2026, nine months ending September 30, 2026 and Annual Report on Form 10-K for the year ending December 31, 2026.


Exhibit 99.1

CARDLYTICS, INC.
Unaudited Pro Forma Condensed Consolidated Balance Sheet
As of December 31, 2025

(Amounts in thousands, except par value amounts)

Historical
(as reported)
Bridg Discontinued Operations (a)Transaction Accounting AdjustmentsPro Forma
Assets
Current assets:
Cash and cash equivalents$48,719 $— $— $48,719 
Accounts receivable and contract assets, net82,669 — — 82,669 
Marketable Securities— — (b)25,416 25,416 
Other receivables2,587 347 — 2,240 
Prepaid expenses and other assets3,304 91 — 3,213 
Total current assets137,279 438 25,416 162,257 
Long-term assets:
Property and equipment, net2,025 94 — 1,931 
Right-of-use assets under operating leases, net4,947 224 — 4,723 
Intangible assets, net5,553 5,553 — — 
Goodwill110,305 — — 110,305 
Capitalized software development costs, net24,214 5,209 — 19,005 
Other long-term assets, net1,318 83 — 1,235 
Total assets$285,641 $11,601 $25,416 $299,456 
Liabilities and stockholders' (deficit) equity
Current liabilities:
Accounts payable$3,360 $705 $— $2,655 
Accrued liabilities:
Accrued compensation6,105 67 — 6,038 
Accrued expenses7,725 600 (c)1,642 8,767 
Partner Share liability24,860 68 — 24,792 
Consumer Incentive liability32,144 — — 32,144 
Deferred revenue2,589 48 — 2,541 
Current operating lease liabilities1,607 169 — 1,438 
Total current liabilities78,390 1,657 1,642 78,375 
Long-term liabilities:
Convertible senior notes, net168,850 — — 168,850 
Line of credit40,070 — — 40,070 
Long-term deferred revenue52 52 — — 
Long-term operating lease liabilities4,787 39 — 4,748 
Total liabilities292,149 1,748 1,642 292,043 
Stockholders’ (deficit) equity:
Common stock, $0.0001 par value10 — — 10 
Additional paid-in capital1,399,542 — — 1,399,542 
Accumulated other comprehensive income(1,996)— — (1,996)
Accumulated deficit(1,404,064)9,853 (d)23,774 (1,390,143)
Total stockholders’ (deficit) equity(6,508)9,853 23,774 7,413 
Total liabilities and stockholders’ (deficit) equity$285,641 $11,601 $25,416 $299,456 


Exhibit 99.1

CARDLYTICS, INC.
Unaudited Pro Forma Condensed Consolidated Statement of Operations
For the Year Ended December 31, 2025

(Amounts in thousands except per share amounts)

 Historical
(as reported)
Bridg Discontinued Operations (a)Pro Forma
Revenue$233,273 $20,947 $212,326 
Costs and expenses:
Partner Share and other third-party costs102,949 1,855 101,094 
Delivery costs25,711 6,463 19,248 
Sales and marketing expense39,478 7,883 31,595 
Research and development expense39,765 5,545 34,220 
General and administrative expense47,267 3,207 44,060 
Acquisition, integration and divestiture costs561 — 561 
Change in contingent consideration102 — 102 
Impairment of goodwill and intangible assets58,843 — 58,843 
Gain on divestiture(4,831)— (4,831)
Depreciation and amortization expense25,244 8,017 17,227 
Total costs and expenses335,089 32,970 302,119 
Operating loss(101,816)(12,023)(89,793)
Other income (expense):
Interest expense, net(7,919)— (7,919)
Foreign currency gain6,247 — 6,247 
Total other expense(1,672)— (1,672)
Loss before income taxes(103,488)(12,023)(91,465)
Net Loss(103,488)(12,023)(91,465)
Net Loss per share, basic and diluted$(1.95)$— $(1.72)
Weighted-average common shares outstanding, basic and diluted53,114 — 53,114 




















Exhibit 99.1

CARDLYTICS, INC.
Unaudited Pro Forma Condensed Consolidated Statement of Operations
For the Year Ended December 31, 2024

(Amounts in thousands except per share amounts)

 Historical
(as reported)
Bridg Discontinued Operations (a)Pro Forma
Revenue$278,298 $22,684 $255,614 
Costs and expenses:
Partner Share and other third-party costs127,761 1,220 126,541 
Delivery costs29,643 6,789 22,854 
Sales and marketing expense52,649 9,387 43,262 
Research and development expense49,607 7,367 42,240 
General and administrative expense56,482 4,131 52,351 
Acquisition, integration and divestiture costs161 46 115 
Change in contingent consideration210 — 210 
Impairment of goodwill and intangible assets131,595 131,521 74 
Depreciation and amortization expense25,689 11,133 14,556 
Total costs and expenses473,797 171,594 302,203 
Operating loss(195,499)(148,910)(46,589)
Other income (expense):
Interest expense, net(5,553)— (5,553)
Foreign currency loss(1,269)— (1,269)
Gain on extinguishment of debt13,017 — 13,017 
Total other income6,195 — 6,195 
Loss before income taxes(189,304)(148,910)(40,394)
Net Loss(189,304)(148,910)(40,394)
Net Loss per share, basic and diluted$(3.91)$— $(0.84)
Weighted-average common shares outstanding, basic and diluted48,361 — 48,361 



















Exhibit 99.1

CARDLYTICS, INC.
Unaudited Pro Forma Condensed Consolidated Statement of Operations
For the Year Ended December 31, 2023

(Amounts in thousands except per share amounts)

 Historical
(as reported)
Bridg Discontinued Operations (a)Pro Forma
Revenue$309,204 $23,779 $285,425 
Costs and expenses:
Partner Share and other third-party costs150,578 671 149,907 
Delivery costs28,248 6,801 21,447 
Sales and marketing expense57,425 8,754 48,671 
Research and development expense51,352 5,606 45,746 
General and administrative expense58,810 2,268 56,542 
Acquisition, integration and divestiture (benefits) costs(6,313)(6,817)504 
Change in contingent consideration1,246 — 1,246 
Impairment of goodwill and intangible assets70,518 70,518 — 
Loss on divestiture6,550 — 6,550 
Depreciation and amortization expense26,460 11,845 14,615 
Total costs and expenses444,874 99,646 345,228 
Operating loss(135,670)(75,867)(59,803)
Other income (expense):
Interest expense, net(2,336)— (2,336)
Foreign currency gain3,304 — 3,304 
Total other income968 — 968 
Loss before income taxes(134,702)(75,867)(58,835)
Net Loss(134,702)(75,867)(58,835)
Net Loss per share, basic and diluted$(3.69)$— $(1.61)
Weighted-average common shares outstanding, basic and diluted36,488 — 36,488 


Exhibit 99.1

CARDLYTICS, INC.
Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements

The Unaudited Pro Forma Condensed Consolidated Balance Sheet and Unaudited Pro Forma Condensed Consolidated Statements of Operations include the following adjustments:

Discontinued Operations:

a.Reflects the discontinued operations of the Bridg business, including associated assets, liabilities, equity and results of operations. In accordance with ASC 205-20, Presentation of Financial Statements - Discontinued Operations, the amounts exclude general corporate overhead costs which were historically allocated, but did not specifically relate to the Bridg business, as they did not meet the discontinued operations criteria. Such allocations included labor and non-labor expenses related to the Company’s corporate support functions (e.g., executive, information technology, human resources, legal, accounting, among others) that historically provided support to Bridg.

Transaction Accounting Adjustments:

b.Reflects stock of $25.4 million received from the Buyer from the sale of Bridg.

c.Reflects approximately $1.6 million of Transaction costs to be incurred subsequent to December 31, 2025.

d.Reflects an estimated gain of $13.9 million related to the Transaction based on the estimate of $25.4 million of consideration less Transaction costs of $1.6 million, less Bridg net assets as of December 31, 2025 of $9.9 million. The actual gain recorded upon close may be subject to change and will be based on amounts as of the close date. Since the Unaudited Pro Forma Condensed Consolidated Statements of Operations only include continuing operations, the estimated gain on sale is not included in any period presented.